PET IMAGING AGENTS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

The global PET imaging agents market is estimated to be valued at USD 3,236.4 Mn in 2026 and is expected to reach USD 6,529.5 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 10.5% from 2026 to 2033. Positron emission tomography (PET) imaging agents (radiotracers or radiopharmaceuticals) are specific chemical compounds labeled with positron-emitting radionuclides that permit non-invasive visualization of metabolic and physiological processes at the molecular scale. PET imaging agents are widely used in oncology, neurology, and cardiology. Major agents include Fluorodeoxyglucose (FDG), Florbetapir, and Flutemetamol, as well as novel amyloid- and tau-targeting tracers, for detection and characterization of diseases.

The global market for PET imaging agents includes the development, production, and distribution of these compounds and is growing as a consequence of advances in radiochemistry, the increasing burden of cancer and neurological disorders, and improved access to molecular imaging. The increasing adoption of precision medicine and personalized diagnostics is also increasing the role of PET imaging agents in clinical decision-making and providing opportunities for pharmaceutical companies, research organizations and healthcare providers.

Market Dynamics

The global PET imaging agents market is driven by the increasing burden of cancer and neurodegenerative disorders, rising demand for accurate detection of disease, and growing clinical application of oncology and neurological radiotracers. The market is also growing due to regulatory approvals of novel PET agents, investments in infrastructure of nuclear medicine, and increasing adoption of PET/Computed Tomography and PET/Magnetic Resonance Imaging, which are improving diagnostic capabilities and clinical applications.

However, a number of constraints are present in the market, such as short radionuclide half-lives pose challenges in terms of production, transportation and supply-chain, while high costs of radiopharmaceutical manufacturing, cyclotron facilities and PET scanners limit access in resource-constrained regions. Nevertheless, next-generation targeted tracers, including prostate-specific membrane antigen and fibroblast activation protein inhibitor agents, alongside the increasing use of theranostics and expansion of nuclear medicine infrastructure across Asia-Pacific, Latin America and the Middle East will offer opportunities within global PET imaging agents market.

Key Features of the Study

• This report provides in-depth analysis of the global PET imaging agents market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global PET imaging agents market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Siemens Healthineers AG, GE HealthCare Technologies Inc., Lantheus Holdings, Inc., Cardinal Health, Inc., Curium, Bracco S.p.A., Bayer AG, Telix Pharmaceuticals Limited, Eckert & Ziegler SE, and Jubilant Pharmova Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global PET imaging agents market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PET imaging agents market

Market Segmentation

• Type Insights (Revenue, USD Mn, 2021 - 2033)
  • Fluorine-18
  • Nitrogen-13
  • Gallium-68
  • Carbon-11
  • Others
• Application Insights (Revenue, USD Mn, 2021 - 2033)
  • Cardiology
  • Oncology
  • Neurology
  • Others
• End User Insights (Revenue, USD Mn, 2021 - 2033)
  • Hospitals
  • Diagnostic Imaging Centers
  • Specialty Clinics
  • Research Institutes
  • Others
• Regional Insights (Revenue, USD Mn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Siemens Healthineers AG
  • GE HealthCare Technologies Inc.
  • Lantheus Holdings, Inc.
  • Cardinal Health, Inc.
  • Curium
  • Bracco S.p.A.
  • Bayer AG
  • Telix Pharmaceuticals Limited
  • Eckert & Ziegler SE
  • Jubilant Pharmova Limited